Related Experiment Video

Updated: May 15, 2026

Genetic Encoding of a Non-Canonical Amino Acid for the Generation of Antibody-Drug Conjugates Through a Fast Bioorthogonal Reaction
11:02

Genetic Encoding of a Non-Canonical Amino Acid for the Generation of Antibody-Drug Conjugates Through a Fast Bioorthogonal Reaction

Published on: September 14, 2018

Antibody-Drug Conjugates: Where the Action Is: ADCs - The New Frontier

Bob Carlson

    Biotechnology Healthcare
    |December 26, 2012
    PubMed

    Insights

    Next-generation antibody-drug conjugates, such as trastuzumab emtansine (T-DM1), are designed for targeted cancer cell destruction with minimal harm to patients. This approach aims to improve treatment efficacy and patient safety in oncology.

    Area of Science:

    • Oncology
    • Pharmacology
    • Molecular Biology

    Background:

    • Antibody-drug conjugates (ADCs) represent a targeted cancer therapy approach.
    • Trastuzumab emtansine (T-DM1) is an example of a next-generation ADC.

    Purpose of the Study:

    • To evaluate the efficacy and safety of T-DM1 in cancer treatment.
    • To highlight the advancements in ADC technology for improved patient outcomes.

    Main Methods:

    • Preclinical studies and clinical trials involving T-DM1.
    • Analysis of tumor response and patient-reported outcomes.

    Main Results:

    • Demonstrated targeted killing of cancer cells by T-DM1.
    • Showcased a favorable safety profile with reduced off-target effects compared to traditional chemotherapy.

    Conclusions:

    • Next-generation ADCs like T-DM1 offer a promising therapeutic strategy.
    • T-DM1 exhibits a dual benefit of potent anti-cancer activity and improved patient tolerability.

    More Related Videos

    Targeted Antibody Blocking by a Dual-Functional Conjugate of Antigenic Peptide and Fc-III Mimetics (DCAF)09:39

    Targeted Antibody Blocking by a Dual-Functional Conjugate of Antigenic Peptide and Fc-III Mimetics (DCAF)

    Published on: September 17, 2019

    Related Concept Videos

    Structure-Activity Relationships and Drug Design01:28

    Structure-Activity Relationships and Drug Design

    Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
    SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence its...
    Phase II Conjugation Reactions: Overview01:14

    Phase II Conjugation Reactions: Overview

    Conjugation, a key component of phase II biotransformation reactions, is a vital process in drug detoxification. It involves transferring endogenous substances like glucuronic acid, sulfate, and glycine to drugs or their metabolites formed in phase I reactions. These conjugation reactions, often catalyzed by specific enzymes, transform potentially harmful metabolites into inactive, water-soluble forms easily excreted in urine or bile. By enhancing polarity and eliminating pharmacological...
    Principles of Drug Action01:24

    Principles of Drug Action

    Drugs are chemical substances that modify biological responses by interacting with macromolecular targets such as receptors, ion channels, transporters, and enzymes. Pharmacodynamics describes the course of action of drugs leading to the physiological effect at a specific site in the body.
    Drugs can be agonists or antagonists. Like the endogenous ligands, agonists always bind and activate the target to produce a cellular response. Agonist binding induces a conformational change which in turn...
    Antibody Actions01:26

    Antibody Actions

    Antibodies, or immunoglobulins, are critical players in the immune system's arsenal against invading pathogens. Produced by B cells and plasma cells, their primary role is to detect and bind to specific antigens, molecules found on the surface of pathogens like bacteria or viruses. Beyond antigen recognition, antibodies perform several vital functions that contribute to immune defense.
    Neutralization
    Antibodies can bind to pathogens, preventing them from infecting host cells. This process...
    Drug Discovery: Overview01:26

    Drug Discovery: Overview

    Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
    Targets for Drug Action: Overview01:26

    Targets for Drug Action: Overview

    Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
    Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...